madrid2i

Resumen

[0000] The present invention relates to a non-human animal model of chronic glaucoma. In addition, the invention refers to a method for the preparation of said animal model, as well as to the use thereof.

Reivindicaciones

CLAIMS 1. A non-human animal mammalian model of chronic glaucoma wherein the animal has intraocular PLGA, PLA or PGA microparticles, optionally loaded, in order to induce a increase in intraocular pressure. 2. A non-human animal mammalian model according to claim 1 wherein de microparticles are loaded with dexamethasone or with a combination of dexamethasone and fibronectin. 3. A non-human animal mammalian model according to any of the previous claims wherein the animal is a rodent, preferably a rat, a mouse or a guinea pig 4. A non-human animal mammalian model according to any of the previous claims wherein chronic glaucoma is open-angle chronic glaucoma. 5. A non-human animal mammalian model according to any of the previous claims wherein the intraocular microparticles optionally loaded have a particle size between 5 μm and 40 μm, preferably between 10 μm and 20 μm. 6. A non-human animal mammalian model according to any of the previous claims wherein the intraocular microparticles optionally loaded are present in the anterior chamber of the eye of the animal. 7. A method for preparing a non-human animal mammalian model of chronic glaucoma according to any of the previous claims comprising the intraocular injection in the animal's eye of a suspension of PLGA, PLA or PGA microparticles optionally loaded. 8. A method according to claim 7 wherein the microparticles are loaded with dexamethasone or with a combination of dexamethasone and fibronectin. 9. A method according to claim 7 or 8 wherein the animal is a rodent, preferably a rat, a mouse or a guinea pig. 10. A method according to claim 7 to 9 wherein the intraocular injection is performed in the anterior chamber of the eye of the animal. 11. A method according to any of previous claims 7 to 10 wherein the aqueous suspension has a concentration of microparticles optionally loaded of 0.005% to 20% by weight of the total suspension. 12. A method according to any of previous claims 7 to 11 wherein 1 to 5 microlitres of the aqueous suspension of microparticles optionally loaded are injected in the animal's eye. 13. A method according to any of previous claims 7 to 12 wherein the microparticles optionally loaded have a particle size between 5 and 40 μm, preferably between 10 μm and 20 μm. 14. Use non-human animal mammalian model according to claim 1 to 7 for the study of physiopathology of glaucoma. 15. Use non-human animal mammalian model according to claim 1 to 7 as a tool for pharmacological, biomaterial and/or surgical studies.

Índice de la ficha

En detalle

Resumen

Reivindicaciones

Etiquetas